We’re thrilled to announce a successful $50M Series B financing round led by Johnson and Johnson Innovation – JJDC, Inc. and joined by a number of leading MedTech investors including S3 Ventures, Lumira Ventures, SV Health Investors, and Deerfield Management.
We’re excited about what’s next. Big things are on the horizon for SpectraWAVE and coronary care!
Learn more here: https://t.co/XRx5nIikwj
#ImageFirst
Congratulations to Dr. Michael Foley and the investigators for the ORBITA-COSMIC trial (PI @rallamee). The trial resulted in reduced angina frequency and improved heart disease related quality of life. And while the imaging endpoint showed no improvement in transmural myocardial perfusion, it did show improvement in subendocardial perfusion, supporting the theorized mechanism of action of the #ShockwaveReducer.
@ACCinTouch
ISI https://t.co/x46wohk9Gd Caution: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada. Please contact your local representative for specific country availability.
Just publ in JSCAI our first-in-human study with a new integrated AI-enabled OCT-NIRS imaging catheter that has enhanced resolution and IVUS-like depth penetration (even better in calcium). Angio co-reg w/ automated EEM, lipid and Ca detection. Free link:
https://t.co/YdgVTAyrA4
@ziadalinyc@EuroInterventio A 10 year journey from the beginning. Can’t wait to see the results. Also, a sincere thanks to so many people that puts so much time and effort into this. @GreggWStone@ziadalinyc
EHJ Case Report:
42 F history of refractory angina. Non-obstructed coronaries. Coronary Sinus Reducer implantation. Symptoms improve. PET images show improvement in blood flow. https://t.co/isZ780TVun
#Neovasc announced the Centers for Medicare and Medicaid Services (CMS) developed favorable new codes.
MORE ON THIS HERE: https://t.co/MQoOQjVJEP
#Cardiac#Catheters#RefractoryAngina @Neovasc